P. Jeffrey Conn, Ph.D.
Lee E. Limbird Professor of Pharmacology
Director, Vanderbilt Program in Drug Discovery
B.S. Psychology/Biology, Lee University, 1981
Ph.D. Pharmacology, Vanderbilt University, 1986
Phone: (615) 936-2189
Fax: (615) 343-3088
Location: 1215D Light Hall
Department of Pharmacology
Vanderbilt University School of Medicine
476 Robinson Research Building
23rd Avenue South at Pierce Avenue
Nashville, TN 37232-6600
Biosketch and Research Interests
Dr. Conn is the Lee E. Limbird Professor of Pharmacology, and founding Director of the Program in Translational Neuropharmacology and the Vanderbilt Program in Drug Discovery. Conn received the Ph.D. degree in Pharmacology from Vanderbilt University in 1986 and pursued postdoctoral studies in the Department of Pharmacology at Yale University. Dr. Conn joined the faculty of the Department of Pharmacology at Emory University in 1988 where he rose to the rank of Full Professor and established himself as a leader in studies of neurotransmitter receptors and their roles in regulating brain function in circuits involved in psychiatric and neurological disorders. In 2000, Dr. Conn moved to Merck and Company to assume the position of Senior Director and Head of the Department of Neuroscience at Merck’s site in West Point, PA. He moved to Vanderbilt University to start a new Program in Drug Discovery, with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics.
Dr. Conn is Editor in Chief of Molecular Pharmacology, Regional Editor (North America) of Current Neuropharmacology and serves on the editorial boards of 6 other international journals. He has served on the Scientific Advisory Boards of multiple companies and currently serves on the Schientific Advisory Boards of the Michael J. Fox Foundation and the Dystonia Medical Research Foundation. He is Chair of the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics (ASPET). He has received numerous awards and honors, including the NARSAD Essel Investigator Distinguished Investigator Award, the Pharmacia-ASPET award in Experimental Therapeutics, the ASPET Astellas Award in Translational Pharmacology, the PhRMA Foundation Award for Excellence in Pharmacology and Toxicology and was named as an ISI Most-Cited Scientists in Pharmacology & Toxicology. He serves on several national and international committees, including International Union of Pharmacology (IUPHAR) subcommittee on receptor nomenclature, Executive Committee, Neuropharmacology Division of ASPET, the ASPET Publications Board of Trust, and is an Expert Consultant, Compound Selection Committee, Treatment Units for Research on Neurocognition and Schizophrenia.
Dr. Conn’s current research is focused on development of novel treatment strategies for schizophrenia, Parkinson’s disease, and other brain disorders.